Drug disappoints in recurrent glioblastoma

5 February 2010 | by Nicola Garrett Print this article Comments Share this article
Hopes for treating recurrent glioblastoma with the targeted anti-angiogenic enzastaurin have been dashed by disappointing phase III results....

Want to read complete article? Please Sign in or Register.

Most viewed articles this week

Recent comments

Related sites